BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 17007742)

  • 41. Hypoglycemic effects of exopolysaccharides produced by mycelial cultures of two different mushrooms Tremella fuciformis and Phellinus baumii in ob/ob mice.
    Cho EJ; Hwang HJ; Kim SW; Oh JY; Baek YM; Choi JW; Bae SH; Yun JW
    Appl Microbiol Biotechnol; 2007 Jul; 75(6):1257-65. PubMed ID: 17457544
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A new, highly selective murine peroxisome proliferator-activated receptor δ agonist increases responsiveness to thermogenic stimuli and glucose uptake in skeletal muscle in obese mice.
    Ngala RA; Stocker CJ; Roy AG; Hislop D; Wargent E; Bell R; Hassall DG; Harling JD; Billin AN; Willson TM; Arch JR; Cawthorne MA
    Diabetes Obes Metab; 2011 May; 13(5):455-64. PubMed ID: 21272187
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Hypoglycemic action of thiazolidinediones/peroxisome proliferator-activated receptor gamma by inhibition of the c-Jun NH2-terminal kinase pathway.
    Díaz-Delfín J; Morales M; Caelles C
    Diabetes; 2007 Jul; 56(7):1865-71. PubMed ID: 17416798
    [TBL] [Abstract][Full Text] [Related]  

  • 44. PAR-1622 is a selective peroxisome proliferator-activated receptor gamma partial activator with preserved antidiabetic efficacy and broader safety profile for fluid retention.
    Kim MK; Chae YN; Kim HS; Choi SH; Son MH; Kim SH; Kim JK; Moon HS; Park SK; Shin YA; Kim JG; Lee CH; Lim JI; Shin CY
    Arch Pharm Res; 2009 May; 32(5):721-7. PubMed ID: 19471887
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Pyridine-2-propanoic acids: Discovery of dual PPARalpha/gamma agonists as antidiabetic agents.
    Humphries PS; Almaden JV; Barnum SJ; Carlson TJ; Do QQ; Fraser JD; Hess M; Kim YH; Ogilvie KM; Sun S
    Bioorg Med Chem Lett; 2006 Dec; 16(23):6116-9. PubMed ID: 16979341
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Design and synthesis of dual peroxisome proliferator-activated receptors gamma and delta agonists as novel euglycemic agents with a reduced weight gain profile.
    Xu Y; Etgen GJ; Broderick CL; Canada E; Gonzalez I; Lamar J; Montrose-Rafizadeh C; Oldham BA; Osborne JJ; Xie C; Shi Q; Winneroski LL; York J; Yumibe N; Zink R; Mantlo N
    J Med Chem; 2006 Sep; 49(19):5649-52. PubMed ID: 16970391
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Effect of saponins from Helicteres isora on lipid and glucose metabolism regulating genes expression.
    Bhavsar SK; Singh S; Giri S; Jain MR; Santani DD
    J Ethnopharmacol; 2009 Jul; 124(3):426-33. PubMed ID: 19505560
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Osthole, a potential antidiabetic agent, alleviates hyperglycemia in db/db mice.
    Liang HJ; Suk FM; Wang CK; Hung LF; Liu DZ; Chen NQ; Chen YC; Chang CC; Liang YC
    Chem Biol Interact; 2009 Oct; 181(3):309-15. PubMed ID: 19682441
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Relationship between peroxisome proliferator-activated receptor-gamma activation and the ameliorative effects of ascochlorin derivatives on type II diabetes.
    Magae J; Tsuruga M; Maruyama A; Furukawa C; Kojima S; Shimizu H; Ando K
    J Antibiot (Tokyo); 2009 Jul; 62(7):365-9. PubMed ID: 19557028
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Comparison of the antidiabetic effects of brain-derived neurotrophic factor and thiazolidinediones in obese diabetic mice.
    Yamanaka M; Itakura Y; Tsuchida A; Nakagawa T; Noguchi H; Taiji M
    Diabetes Obes Metab; 2007 Nov; 9(6):879-88. PubMed ID: 17924870
    [TBL] [Abstract][Full Text] [Related]  

  • 51. FK-614, a selective peroxisome proliferator-activated receptor gamma agonist, improves peripheral glucose utilization while decreasing hepatic insulin extraction in alloxan-induced diabetic dogs.
    Uchino H; Kim T; Lam TK; Yoshii H; Klement P; Williams W; Kawamori R; Giacca A
    Metabolism; 2005 Sep; 54(9):1250-8. PubMed ID: 16125538
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Halofenate is a selective peroxisome proliferator-activated receptor gamma modulator with antidiabetic activity.
    Allen T; Zhang F; Moodie SA; Clemens LE; Smith A; Gregoire F; Bell A; Muscat GE; Gustafson TA
    Diabetes; 2006 Sep; 55(9):2523-33. PubMed ID: 16936200
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Pyridine-3-propanoic acids: Discovery of dual PPARalpha/gamma agonists as antidiabetic agents.
    Humphries PS; Bailey S; Almaden JV; Barnum SJ; Carlson TJ; Christie LC; Do QQ; Fraser JD; Hess M; Kellum J; Kim YH; McClellan GA; Ogilvie KM; Simmons BH; Skalitzky D; Sun S; Wilhite D; Zehnder LR
    Bioorg Med Chem Lett; 2006 Dec; 16(23):6120-3. PubMed ID: 16973358
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The establishment of a novel non-alcoholic steatohepatitis model accompanied with obesity and insulin resistance in mice.
    Cong WN; Tao RY; Tian JY; Liu GT; Ye F
    Life Sci; 2008 May; 82(19-20):983-90. PubMed ID: 18417155
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Metabolic action of peroxisome proliferator-activated receptor gamma agonism in rats with exogenous hypercorticosteronemia.
    Berthiaume M; Laplante M; Tchernof A; Deshaies Y
    Int J Obes (Lond); 2007 Nov; 31(11):1660-70. PubMed ID: 17579631
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Design and synthesis of oxime ethers of alpha-acyl-beta-phenylpropanoic acids as PPAR dual agonists.
    Oon Han H; Kim SH; Kim KH; Hur GC; Joo Yim H; Chung HK; Ho Woo S; Dong Koo K; Lee CS; Sung Koh J; Kim GT
    Bioorg Med Chem Lett; 2007 Feb; 17(4):937-41. PubMed ID: 17157019
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Synthesis and anti-diabetic activity of (RS)-2-ethoxy-3-{4-[2-(4-trifluoro-methanesulfonyloxy-phenyl)-ethoxy]-phenyl}-propionic acid.
    Cai ZF; Liu Q; Li PP; Guo ZR; Shen ZF
    Acta Pharmacol Sin; 2006 May; 27(5):597-602. PubMed ID: 16626515
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Quantitative image analysis in adipose tissue using an automated image analysis system: differential effects of peroxisome proliferator-activated receptor-alpha and -gamma agonist on white and brown adipose tissue morphology in AKR obese and db/db diabetic mice.
    Okamoto Y; Higashiyama H; Inoue H; Kanematsu M; Kinoshita M; Asano S
    Pathol Int; 2007 Jun; 57(6):369-77. PubMed ID: 17539968
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Combination of dipeptidylpeptidase IV inhibitor and low dose thiazolidinedione: preclinical efficacy and safety in db/db mice.
    Roy S; Khanna V; Mittra S; Dhar A; Singh S; Mahajan DC; Priyadarsiny P; Davis JA; Sattigeri J; Saini KS; Bansal VS
    Life Sci; 2007 Jun; 81(1):72-9. PubMed ID: 17532347
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Molecular activation of PPARgamma by angiotensin II type 1-receptor antagonists.
    Erbe DV; Gartrell K; Zhang YL; Suri V; Kirincich SJ; Will S; Perreault M; Wang S; Tobin JF
    Vascul Pharmacol; 2006 Sep; 45(3):154-62. PubMed ID: 16765099
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.